Challenges in Treating Bone Marrow Cancer

Understanding Multiple Myeloma

Bone marrow cancer presents significant treatment challenges, particularly in the case of multiple myeloma. This serious form of cancer arises when an excessive number of plasma cells, a specialized type of blood cell, proliferate within the bone marrow. The overproduction of these plasma cells can lead to the suppression of normal blood cell function. Common symptoms include bone pain, increased susceptibility to fractures, and frequent infections.

Current Treatment Approaches

The standard treatment for multiple myeloma typically begins with aggressive chemotherapy aimed at reducing the plasma cell population in the bone marrow. Younger and healthier patients may undergo a bone marrow transplant followed by additional chemotherapy, which often results in remission. During remission, patients appear healthy and show no signs of cancer. However, it is important to note that multiple myeloma is generally considered incurable, and recurrence is common. To address this, some physicians administer low doses of chemotherapy drugs as part of a “maintenance” therapy, which is thought to prolong remission.

Recent Study on Lenalidomide Maintenance Therapy

Study Overview

A recent study conducted in the UK investigated the effectiveness of lenalidomide as a maintenance therapy for multiple myeloma. This research involved nearly 2,000 patients, with over 1,000 participants randomly assigned to receive lenalidomide while the remaining patients were closely monitored without the drug. The study spanned up to six years, and its findings were published in The Lancet Oncology.

Impact on Patient Lifespan

The results indicated that lenalidomide maintenance therapy significantly extended the average lifespan for patients under 65 years old or those who had undergone a bone marrow transplant. Among transplant recipients, 80% were alive three years post-treatment, which increased to 88% with lenalidomide. However, patients unable to undergo a transplant saw no improvement in survival odds, as only 68% were alive after three years, and the treatment had no effect on those over 65 years.

Effect on Relapse Rates

Quality of life is a critical consideration for cancer patients, particularly regarding the duration of remission. Initially, patients experienced an average remission period of 20 months, which lenalidomide nearly doubled to 39 months. Unfortunately, relapses are common with multiple myeloma, often requiring further intensive chemotherapy. Without lenalidomide, 39% of patients in the study experienced a second relapse or died, while the drug reduced this rate to 25%.

Potential Risks of Lenalidomide

While lenalidomide shows promise, it also carries risks. Chemotherapy drugs can sometimes lead to the development of secondary cancers. In this study, 5% of patients on lenalidomide developed new cancers within the first three years, compared to 3% in the control group. Additionally, 15% of the patients had to discontinue lenalidomide due to treatment-related complications.

Considerations for Future Treatments

Limitations of the Study

Despite the encouraging findings, the study had limitations. It was not double-blinded, meaning both patients and doctors were aware of who received lenalidomide, which could introduce a placebo effect. There is also the possibility that patients receiving lenalidomide received more attentive care than those in the control group. Furthermore, the researchers did not directly assess the treatment’s impact on quality of life, an essential factor in cancer care.

Conclusion and Future Outlook

Despite these limitations, researchers remain optimistic about the findings. Long-term lenalidomide treatment appears to extend remission periods for multiple myeloma patients and improve survival rates for younger patients and those with transplants. This study contributes valuable insights into the treatment landscape for this challenging disease.

References

Jackson, G. H., F. E. Davies, C. Pawlyn, D. A. Cairns, A. Striha, C. Collett, A. Hockaday, J. R. Jones, B. Kishore, M. Garg, C. D. Williams, K. Karunanithi, J. Lindsay, M. W. Jenner, G. Cook, N. H. Russell, M. F. Kaiser, M. T. Drayson, R. G. Owen, W. M. Gregory and G. J. Morgan (2018). “Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.” The Lancet Oncology. https://doi.org/10.1016/S1470-2045(18)30687-9

“Treatment shown to improve the odds against bone marrow cancer” (2018). Newcastle University. https://www.eurekalert.org/pub_releases/2018-12/nu-tst121418.php

“Multiple myeloma” (2018). Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/multiple-myeloma/